Calebiro D, Bathon K, Weigand I
Institute of Pharmacology and Toxicology, University Hospital, University of Würzburg, Würzburg, Germany.
Department of Medicine I, Endocrine and Diabetes Unit, University Hospital, University of Würzburg, Würzburg, Germany.
Horm Metab Res. 2017 Apr;49(4):307-314. doi: 10.1055/s-0042-112817. Epub 2016 Nov 3.
Somatic mutations in , coding for the catalytic α subunit of protein kinase A (PKA), have been recently identified as the most frequent genetic alteration in cortisol-secreting adrenocortical adenomas, which are responsible for adrenal Cushing's syndrome. The mutations identified so far lie at the interface between the catalytic (C) and regulatory (R) subunit of PKA. Detailed functional studies of the most frequent of these mutations (L206R) as well as of another one in the same region of the C subunit (199_200insW) have revealed that these mutations cause constitutive activation of PKA and lack of regulation by cAMP. This is due to interference with the binding of the R subunit, which keeps the C subunit inactive in the absence of cyclic AMP. Here, we review these recent findings, with a particular focus on the mechanisms of action of mutations.
编码蛋白激酶A(PKA)催化α亚基的基因发生体细胞突变,最近被确定为分泌皮质醇的肾上腺皮质腺瘤中最常见的基因改变,而肾上腺皮质腺瘤是导致肾上腺库欣综合征的原因。迄今为止发现的突变位于PKA的催化(C)亚基和调节(R)亚基之间的界面处。对这些最常见突变(L206R)以及C亚基同一区域的另一个突变(199_200insW)进行的详细功能研究表明,这些突变会导致PKA的组成性激活且不受cAMP调节。这是由于干扰了R亚基的结合,在没有环磷酸腺苷的情况下,R亚基会使C亚基保持无活性状态。在此,我们回顾这些最新发现,特别关注该基因突变的作用机制。